<DOC>
	<DOCNO>NCT02872714</DOCNO>
	<brief_summary>The purpose study evaluate overall response rate ( ORR ) INCB054828 monotherapy treatment metastatic surgically unresectable urothelial carcinoma harbor FGF/FGFR alteration .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety INCB054828 Subjects With Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>Histologically document metastatic surgically unresectable urothelial carcinoma ; may include primary site ureter , upper tract , renal pelvis , bladder . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Life expectancy â‰¥ 12 week . Radiographically measurable evaluable disease per RECIST v1.1 . Known FGF/FGFR alteration sponsor 's central laboratory either 1 ) fail least 1 previous treatment metastatic surgically unresectable urothelial carcinoma ( ie , chemotherapy , immunotherapy ) 2 ) platinum ineligible . Prior receipt selective FGFR inhibitor . Use potent CYP3A4 inhibitor inducer within 14 day 5 half life ( whichever short ) first dose study drug . Inability unwillingness swallow INCB054828 significant gastrointestinal disorder ( ) could interfere absorption , metabolism , excretion INCB054828 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Urothelial carcinoma</keyword>
	<keyword>fibroblast growth factor ( FGF )</keyword>
	<keyword>fibroblast growth factor receptor ( FGFR )</keyword>
	<keyword>FGF/FGFR alteration</keyword>
</DOC>